Nice, solid chunk up, for a change. I was getting worried Tankogen would be entirely sitting out the long-awaited biotech boom, when it was one of the first true break-through companies, finally blossoming. Been here since the early 90's, and didn't think it would take this long, but still keeping the faith.
with Kadcyla approval IMGN has very low downside risk and significant growth potential. Compared to SGEN and CLDX, IMGN is 50-100% undervalued now with the potential to make a PCYC run in the next 12-18 months. IMGN pipeline should finally produce some data in 2014.
I voted against the current BOD and the compensation plan, Junius is waaaay overpaid and needs to go. BOD is negligent and absent. I probably should have voted for the one director that actually bought a little stock, but did not.
Stock is acting strong today, I hope they don't pull a MEDX and sell the company just before the pipeline matures on the cheap and without an auction to the highest bidder..